Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WHR1 | P49842 | 1/20 | 0.75 |
| ▸ | EHMT2 | Q96KQ7 | 16/20 | 0.73 |
| ▸ | KDM1A | O60341 | 12/20 | 0.73 |
| ▸ | RCOR1 | Q9UKL0 | 12/20 | 0.73 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.62 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.62 |
| ▸ | SPIN1 | Q9Y657 | 1/20 | 0.62 |
| ▸ | EHMT1 | Q9H9B1 | 6/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9911814 | 0.89 | EHMT2 (0.91) | WHR1EHMT2KDM1ARCOR1EZH2 | |
| SCHEMBL22144597 | 0.86 | WHR1 (1.00) | WHR1EHMT2KDM1ARCOR1SPIN1 | |
| SCHEMBL4193833 | 0.84 | EHMT2 (0.89) | WHR1EHMT2KDM1ARCOR1EZH2 | |
| SCHEMBL1428017 | 0.80 | EHMT2 (0.74) | WHR1EHMT2KDM1ARCOR1EHMT1 | |
| SCHEMBL15280227 | 0.79 | EHMT2 (1.00) | EHMT2KDM1ARCOR1EZH2PRMT1 | |
| SCHEMBL1427723 | 0.78 | EHMT2 (0.75) | WHR1EHMT2KDM1ARCOR1EZH2 | |
| SCHEMBL31351168 | 0.78 | EHMT1 (0.73) | EHMT2KDM1ARCOR1EHMT1HDAC1 | |
| SCHEMBL27223858 | 0.77 | EHMT2 (0.83) | EHMT2KDM1ARCOR1EHMT1HDAC1 | |
| SCHEMBL21499812 | 0.77 | EHMT2 (0.73) | EHMT2KDM1ARCOR1EHMT1HDAC1 | |
| SCHEMBL21486655 | 0.77 | EHMT2 (0.81) | WHR1EHMT2KDM1ARCOR1EHMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193203-B2 | Bicyclic compounds having activity at the CXCR4 receptor | ALLERGAN, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| EP-2300456-A1 | BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR | Allergan, Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| US-20090312305-A1 | BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR | ALLERGAN, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| WO-2009143058-A1 | BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR | ALLERGAN, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| US-7608402-B2 | DNA methylation specific signal amplification | LI WEIWEI | 2009-10-27 | — | — | US | disclosed |
| US-20090181373-A1 | DNA methylation specific signal amplification | LI WEIWEI | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312305-A1 | BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR | CXCR4, CXCR2, CXCL12 | WHR1 2532/4885EHMT2 4669/4885KDM1A 4804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.